SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Omar Hamdy)
 

Search: WFRF:(Omar Hamdy) > (2010-2014) > High incidence of c...

High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden : graft-versus-leukemia effect protects against relapse

Machaczka, Maciej (author)
Karolinska Institutet,Division of Hematology, Department of Medicine at Huddinge, Karolinska Institutet, Stockholm, Sweden; Hematology Center Karolinska, Karolinska University Hospital, Huddinge M54, 141 86 Stockholm, Sweden
Johansson, Jan-Erik (author)
Department of Hematology and Coagulation, Sahlgrenska University Hospital, Göteborg, Sweden
Remberger, Mats (author)
Karolinska Institutet,Division of Clinical Immunology and Transfusion Medicine, Karolinska Institute, Stockholm, Sweden
show more...
Hallböök, Helene (author)
Karolinska Institutet,Uppsala universitet,Hematologi,Department of Hematology, Uppsala University Hospital, Uppsala, Sweden
Lazarevic, Vladimir Lj (author)
Lund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine,Department of Hematology, Skåne University Hospital, Lund University, Lund, Sweden
Wahlin, Björn Engelbrekt (author)
Karolinska Institutet,Division of Hematology, Department of Medicine at Huddinge, Karolinska Institutet, Stockholm, Sweden; Hematology Center Karolinska, Karolinska University Hospital, Huddinge M54, 141 86 Stockholm, Sweden
Omar, Hamdy (author)
Karolinska Institutet,Division of Hematology, Department of Medicine at Huddinge, Karolinska Institutet, Stockholm, Sweden; Hematology Center Karolinska, Karolinska University Hospital, Huddinge M54, 141 86 Stockholm, Sweden
Wåhlin, Anders (author)
Umeå universitet,Umeå University,Institutionen för strålningsvetenskaper
Juliusson, Gunnar (author)
Lund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine,Department of Hematology, Skåne University Hospital, Lund University, Lund, Sweden
Kimby, Eva (author)
Karolinska Institutet,Division of Hematology, Department of Medicine at Huddinge, Karolinska Institutet, Stockholm, Sweden; Hematology Center Karolinska, Karolinska University Hospital, Huddinge M54, 141 86 Stockholm, Sweden
Hägglund, Hans (author)
Uppsala universitet,Karolinska Institutet,Hematologi,Division of Hematology, Department of Medicine at Huddinge, Karolinska Institutet, Stockholm, Sweden; Hematology Center Karolinska, Karolinska University Hospital, Huddinge M54, 141 86 Stockholm, Sweden
show less...
 (creator_code:org_t)
2013-11-09
2013
English.
In: Medical Oncology. - : Springer Science and Business Media LLC. - 1559-131X .- 1357-0560. ; 30:4, s. 762-762
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a potentially curative treatment option for eligible patients with chronic lymphocytic leukemia (CLL). However, it is known that cure of CLL is only possible if a graft-versus-leukemia effect is present. Between 1994 and 2007, 48 adults underwent allo-SCT for poor-risk CLL in Sweden. Of these, ten (21%) patients aged 24-53 years (median: 46 years) received myeloablative conditioning (MAC), based on TBI and cyclophosphamide. All MAC patients had refractory, poorly controlled CLL before allo-SCT (partial remission in 9/10 patients and progressive disease in one). The cumulative incidence of acute graft-versus-host disease (GVHD) grades II-IV was 30%. Nine patients developed chronic GVHD; extensive in four. Rates of nonrelapse mortality at 1, 3 and 10 years were 0, 10 and 20%, respectively. Two patients relapsed 36 and 53 months after transplantation. Six patients were still alive after a median follow-up time of 11.5 years (range 5.9-13.7). The probabilities of relapse-free and overall survival from 1, 3 and 5 years after transplantation were 100, 90 and 70%, and 100, 90 and 80%, respectively. Nevertheless, our analysis of long-term outcome after MAC allo-SCT for CLL suggests that younger patients with poorly controlled CLL may benefit from MAC allo-SCT.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Keyword

Adult
Disease Progression
Female
Graft vs Host Disease
Graft vs Leukemia Effect
Hematopoietic Stem Cell Transplantation
Humans
Kaplan-Meier Estimate
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Middle Aged
Sweden
Transplantation, Homologous
Young Adult
Allogeneic stem cell transplantation

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view